CranioSense Inc. Announces Collaboration and Licensing Agreement with Vivonics Inc. for the Development and Commercialization of IPASS
Bedford, Mass.—Feb. 6, 2023—CranioSense, Inc., an early-stage clinical company developing solutions for assessing and monitoring brain health, announced today that it has entered into an exclusive license agreement with Vivonics, Inc. for its intellectual property related to non-invasive intracranial pressure monitoring.
With this intellectual property, CranioSense is developing a device called IPASS to help clinicians and healthcare providers rapidly and easily diagnose cerebral hypertension, which, if left undiagnosed and untreated, can lead to secondary brain damage.
Ryan Myers, President & CEO of CranioSense, says "IPASS will be a first-in-class solution that addresses a significant global unmet need. We believe that by bringing IPASS to market we can dramatically reduce the time to diagnose cerebral hypertension, thus improving outcomes for patients suffering from elevated intracranial pressure."
"We are excited to have entered a licensing deal with Vivonics, providing us access to the deep knowledge and history with which they have developed in this space over the past decade."
Under the terms of the agreement, Vivonics granted CranioSense an exclusive license to develop and commercialize IPASS globally.
About CranioSense
CranioSense, Inc. is an early-stage clinical company developing solutions for diagnosing and monitoring brain health.
CranioSense is a wholly owned subsidiary of Vivonics, formed in 2022 to bring Vivonics brain health solutions to market. IPASS will be CranioSense's first commercial entry.
For more information, please visit the company's website at
About Vivonics
Vivonics' mission is to improve human health, wellness, and performance in diverse and challenging environments by developing innovative, non-invasive physiological monitoring, diagnostic, and decision-support technologies.
After successfully developing solutions for unmet health and wellness needs, Vivonics looks for commercialization partnerships to bring the new technology to market.
Over the years, Vivonics has licensed and entered multiple technology partnerships. However, CranioSense will be Vivonics' first spin-out of an internally incubated technology.
For more information, please visit the company's website at